Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
Fast base station switching method and system, and hierarchical zone-based fast handoff approach
Vibration disturbance estimation and control
Manufacturing method power semiconductor device
Data processing apparatus, activation control method, and computer-readable storage medium
Semiconductor device manufacturing method and device for same
Probiotic Bifidobacterium strains
Protective vest
  Randomly Featured Patents
Device and method for the quantified evaluation of surface characteristics
Method of manufacturing x-ray mask blank and method of manufacturing x-ray membrane for x-ray mask
Phototherapy apparatus
Semiconductor memory device and connecting method of sense amplifier
Battery separator having a puncture-proof border
Suspension and retraction system for endoscopic surgery and method for using same
Display and pixel circuit thereof
Continuous high pressure solids pump system
Canvas stretching system with corner clamps